Qualigen therapeutics' pan-ras inhibitor program highlighted in two abstracts at american society of clinical oncology (asco) 2023 annual meeting

Abstracts feature preclinical data in (1) pancreatic cancer and (2) luminal b breast cancer
QLGN Ratings Summary
QLGN Quant Ranking